Biogen Maintains Mixed Ratings as Analysts Disagree on Stock

Analyst Emily Field from Barclays has maintained a Hold rating on Biogen (BIIB), with a price target of $200.00. This comes after a report released by Citi's Geoff Meacham, who also gave Biogen a Hold rating, while Mizuho Securities maintained a Buy rating on the same day.

Biogen reported its latest earnings for the quarter ending June 30, with revenue at $2.74 billion and a net profit of $97.5 million. This compares to last year's revenue of $2.65 billion and net profit of $634.8 million.

Field has a 3-star rating on TipRanks, with an average return of 2.0% and a success rate of 45.45%. She covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Merck & Company, and AbbVie.

In addition to Biogen's earnings report, corporate insider activity has also been under scrutiny. According to TipRanks, there have been 31 insiders selling their shares of BIIB in recent months, resulting in a negative sentiment towards the stock. For example, Lloyd Minor, a Director at BIIB, sold 1,186.00 shares for $239,749.90 earlier this month.